- Home
- IDYA vs HNI Comparison
IDYA vs HNI Comparison
Compare IDYA & HNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- HNI
- Stock Information
- Founded
- IDYA 2015
- HNI 1944
- Country
- IDYA United States
- HNI United States
- Employees
- IDYA N/A
- HNI N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- HNI Office Equipment/Supplies/Services
- Sector
- IDYA Health Care
- HNI Consumer Discretionary
- Exchange
- IDYA Nasdaq
- HNI Nasdaq
- Market Cap
- IDYA 2.3B
- HNI 2.1B
- IPO Year
- IDYA 2019
- HNI N/A
- Fundamental
- Price
- IDYA $27.16
- HNI $46.72
- Analyst Decision
- IDYA Buy
- HNI Strong Buy
- Analyst Count
- IDYA 14
- HNI 1
- Target Price
- IDYA $49.17
- HNI $70.00
- AVG Volume (30 Days)
- IDYA 953.6K
- HNI 722.0K
- Earning Date
- IDYA 11-03-2025
- HNI 10-28-2025
- Dividend Yield
- IDYA N/A
- HNI 2.94%
- EPS Growth
- IDYA N/A
- HNI 30.07
- EPS
- IDYA N/A
- HNI 3.08
- Revenue
- IDYA $7,000,000.00
- HNI $2,581,500,000.00
- Revenue This Year
- IDYA $62.30
- HNI $5.80
- Revenue Next Year
- IDYA $285.58
- HNI $3.78
- P/E Ratio
- IDYA N/A
- HNI $15.00
- Revenue Growth
- IDYA N/A
- HNI N/A
- 52 Week Low
- IDYA $13.45
- HNI $39.76
- 52 Week High
- IDYA $39.30
- HNI $58.42
- Technical
- Relative Strength Index (RSI)
- IDYA 70.30
- HNI 56.07
- Support Level
- IDYA $24.04
- HNI $44.13
- Resistance Level
- IDYA $25.39
- HNI $45.41
- Average True Range (ATR)
- IDYA 1.05
- HNI 0.87
- MACD
- IDYA 0.16
- HNI 0.45
- Stochastic Oscillator
- IDYA 99.45
- HNI 90.11
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About HNI HNI Corporation
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.